The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10917 malaria professionals are enjoying the free benefits of MalariaWorld today

malaria chemoprevention

Effect of Seasonal Malaria Chemoprevention on Immune Markers of Exhaustion and Regulation

January 7, 2020 - 14:26 -- Open Access
Attaher O, Zaidi I, Duffy PE, et al.
The Journal of Infectious Diseases, Volume 221, Issue 1, 1 January 2020, Pages 138–145

Seasonal malaria chemoprevention (SMC) is a novel strategy to reduce malaria infections in children. Infection with Plasmodium falciparum results in immune dysfunction characterized by elevated expression of markers associated with exhaustion, such as PD1 and LAG3, and regulatory CD4+FOXP3+ T cells.

Clinical diagnostic evaluation of HRP2 and pLDH-based rapid diagnostic tests for malaria in an area receiving seasonal malaria chemoprevention in Niger

December 30, 2019 - 15:06 -- Open Access
Matthew E. Coldiron, Bachir Assao, Rebecca F. Grais, et al.
Malaria Journal 2019 18:443, 26 December 2019

Rapid diagnostic tests (RDT) for malaria are common, but their performance varies. Tests using histidine-rich protein 2 (HRP2) antigen are most common, and many have high sensitivity. HRP2 tests can remain positive for weeks after treatment, limiting their specificity and usefulness in high-transmission settings. Tests using Plasmodium lactate dehydrogenase (pLDH) have been less widely used but have higher specificity, mostly due to a much shorter time to become negative.

Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention

December 30, 2019 - 14:13 -- Open Access
Marit van Lenthe, Renske van der Meulen, Cally Roper, et al.
Malaria Journal 2019 18:430, 18 December 2019

Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC). However, SP efficacy is threatened by drug resistance, that is conferred by mutations in the dhfr and dhps genes. The World Health Organization has specified that intermittent preventive treatment for infants (IPTi) with SP should be implemented only if the prevalence of the dhps K540E mutation is under 50%. There are limited current data on the prevalence of resistance-conferring mutations available from Eastern DRC. The current study aimed to address this knowledge gap.

Subscribe to RSS - malaria chemoprevention